Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer
2022年8月24日 - 5:30PM
COMPANY ANNOUNCEMENT – NO. 36 / 2022
Copenhagen, DK and Boston, MA, August 24,
2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)
(CVR-no. 20045078), a biotechnology company focused on the
discovery and development of innovative peptide-based medicines,
today announced the appointment of Henriette Wennicke as Zealand’s
Chief Financial Officer starting November 1, 2022.
Henriette Wennicke comes to Zealand with broad finance and
business experience at large organizations, including in
healthcare, where she has led financial planning and R&D
portfolio management. She is currently the Vice President and Head
of Investor Relations and Treasury at GN Store Nord, a global
leader in intelligent audio solutions, listed on the Nasdaq
Copenhagen. Previously, Henriette Wennicke was Vice President and
Head of Global Finance at GN Hearing. Henriette Wennicke started
her career at Novo Nordisk, where she held various finance
positions of increasing responsibility within the R&D
organization during her 10-year tenure.
“Henriette brings a track record of leadership in finance and
business strategy, and we are thrilled to welcome her to Zealand at
this important juncture for the company,” said Adam Steensberg,
Chief Executive Officer, Zealand Pharma. “We look forward to
working alongside her as we continue to grow and advance our
pipeline of peptide-based therapeutics.”
“I am excited and honored to be joining Zealand Pharma, and
delighted to be returning to the healthcare industry,” said
Henriette Wennicke. “I look forward to working with the team to
fully leverage the value of Zealand’s rich R&D pipeline and
contribute to the strong momentum the company is building.”
Henriette Wennicke holds an M.Sc. in Finance and Strategic
Management from Copenhagen Business School. She will succeed
Matthew Dallas, who joined Zealand as CFO in 2019, and will leave
the company at the end of August. Lykke Rømer, Vice President, Head
of Finance and Accounting will assume the responsibilities of the
CFO on an interim basis.
# # #
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq:
ZEAL) ("Zealand") is a biotechnology company focused on the
discovery and development of peptide-based medicines. More than 10
drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In addition, license
collaborations with Boehringer Ingelheim and AstraZeneca create
opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please visit
http://www.zealandpharma.com.
Forward-Looking StatementThis press release contains
“forward-looking statements”, as that term is defined in the
Private Securities Litigation Reform Act of 1995, as amended, that
provide Zealand Pharma’s expectations or forecasts of future events
regarding the research, development and commercialization of
pharmaceutical products. These forward-looking statements may be
identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “possible,” “potential,” “will,” “would” and other words
and terms of similar meaning. You should not place undue reliance
on these statements, or the scientific data presented. The reader
is cautioned not to rely on these forward-looking statements. Such
forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions, which may cause actual results to differ
materially from expectations set forth herein and may cause any or
all of such forward-looking statements to be incorrect, and which
include, but are not limited to, the occurrence of adverse safety
events; risks of unexpected costs or delays; unexpected concerns
that may arise from additional data, analysis or results obtained
during clinical trials; failure to protect and enforce our data,
intellectual property and other proprietary rights and
uncertainties relating to intellectual property claims and
challenges; regulatory authorities may require additional
information or further studies, or may fail to approve or may delay
approval of our drug candidates or expansion of product labelling;
failure to obtain regulatory approvals in other jurisdictions;
product liability claims; and the direct and indirect impacts of
the ongoing COVID-19 pandemic on our business, results of
operations and financial condition. If any or all of such
forward-looking statements prove to be incorrect, our actual
results could differ materially and adversely from those
anticipated or implied by such statements. The foregoing sets forth
many, but not all, of the factors that could cause actual results
to differ from our expectations in any forward-looking statement.
All such forward-looking statements speak only as of the date of
this press release and are based on information available to
Zealand Pharma as of the date of this release. We do not undertake
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof. Information
concerning pharmaceuticals (including compounds under development)
contained within this material is not intended as advertising or
medical advice.
Contact:
Anna Krassowska, PhDVice President, Investor Relations &
Corporate CommunicationsZealand PharmaEmail:
ank@zealandpharma.com
David Rosen (U.S. Media)Argot PartnersEmail:
media@zealandpharma.com
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 5 2024 まで 6 2024
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 6 2023 まで 6 2024